The Food and Drug Administration on Tuesday approved a once-daily version of Abbott Laboratories' HIV protease inhibitor Kaletra, The Wall Street Journal reports. The drug had previously been approved for twice-daily dosage. A 48-week study of 190 treatment-naive HIV-positive adults showed that once-daily dosing of the medication was as effective in controlling HIV viral replication as twice-daily dosing. Kaletra, the most frequently prescribed protease inhibitor in the United States, is recommended by the Department of Health and Human Services for use in first-line HIV therapy along with Epivir and either Retrovir or Zerit. The new once-daily formulation of Kaletra will be offered in both liquid and soft gel capsules, say Abbott officials.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















